Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 8 clinical trials
ECOSPOR III: A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults

(Treatment Group I [SER-109] or Treatment Group II [Placebo]) and stratified by age (<65 years; ≥65 years), as well as antibiotic regimen for the qualifying episode (vancomycin; fidaxomicin).

antibiotic therapy
clostridium difficile
  • 21 Dec, 2020
  • 72 locations
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

The first line therapy for an initial episode of CDI (Clostridium difficile infection) is 10-14 days of oral vancomycin which is now recommended over metronidazole in the 2018 guidelines from the Association of Medical Microbiologists and Infectious Diseases of Canada (AMMI). Although response rates for the treatment of a first …

  • 24 Jun, 2021
  • 1 location
Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection

severe and fulminant CDI. Current evidence suggests that FMT in combination with vancomycin is required, and that multiple treatments are necessary. The investigators think fidaxomicin may be a better

  • 24 Jan, 2021
  • 1 location
Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection

This is a medical research study designed to look at the safety and efficacy of 30-day course of fidaxomicin for treatment of recurrent CDI (Clostridium difficile Infection). CDI is an infection

stool test
clostridium difficile
  • 23 Jan, 2021
  • 2 locations
A Study of ART24 in Subjects Recently Cured of a Clostridium Difficile Infection (CDI)

This is a randomized, placebo-controlled, double-blind, multi-site study in which 16 subjects with a recent C. difficile infection (CDI) who have completed a standard of care course of CDI antibiotics and have achieved clinical cure based on signs and symptoms, will be randomized to 7 or 28 daily doses of …

  • 31 May, 2021
  • 10 locations
Treatment of Mild-moderate Clostridium Difficile Infection (CDI)

Patients diagnosed to have mild-moderate CDI will be randomized to receive IM-01 egg-derived anti-C. difficile polyclonal antibodies in increasing dosages, twice daily, for a total of 10 14 days. Resolution of diarrhea and other symptoms and fecal test parameters will be used to assess clinical effectiveness of Immunotherapy with IM-01 …

  • 23 Jan, 2021
  • 1 location
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection

C-diff infection often causes belly pain and diarrhea and can be very hard to treat with medicine. One of the possible reasons that C-diff infection is hard to treat is because there is too much "bad" bacteria in the colon. Investigators believe that putting more "good" bacteria into the colon …

  • 25 Jan, 2021
  • 1 location
Optimal Treatment for Recurrent Clostridium Difficile

The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of

  • 18 Jul, 2021
  • 32 locations